Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy

作     者：Rui Ma Xiao-Jun Huang Jin-Song Jia Jun Kong Ya-Zhen Qin Hao Jiang 

作者机构：Peking University Institute of HematologyPeking University People's HospitalBeijing 100044China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2019年第132卷第20期

页      面：2498-2500页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by a grant from the Beijing Municipal Science & Technology Commission 

主　　题：neoplasms myeloid PDGFRA 

摘      要：To the Editor: The presence of FIP-1-like-1-platelet-derived growth factor receptor-α (FIP1L1-PDGFRA, F/P) fusion gene accounts for approximately 23% (3%-56%) of all eosinophilias.[1] From 2008, the World Health Organization (WHO) classification redefined this disease as myeloid/lymphoid neoplasms with eosinophilia and PDGFRA rearrangement, now constituting a distinct type of hematopoietic disorders. F/P fusion is a tyrosine kinase and is therefore sensitive to tyrosine kinase inhibitors (TKIs).